Advanced Oncotherapy PLC Update on admission of Subscription Shares (6147K)
03 September 2021 - 4:00PM
UK Regulatory
TIDMAVO
RNS Number : 6147K
Advanced Oncotherapy PLC
03 September 2021
3 September 2021
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Update on admission of Subscription Shares
Advanced Oncotherapy (AIM: AVO), the developer of
next-generation proton therapy systems for cancer treatment,
announces that further to the announcements released by the Company
on 11 August 2021 and 31 August 2021, settlement of the
Subscription that is subject to the First Admission is now expected
to complete within the next two weeks. Once funds have been
received in full, application will be made to the London Stock
Exchange for the 82,383,761 Subscription Shares and the 6,470,880
new ordinary shares in respect of the fee arrangements set out in
the Company's announcement of 11 August 2021 to be admitted to
trading on AIM ("Admission").
The remaining 11,145,405 Subscription Shares that are subject to
the Second Admission are expected to be admitted to trading on AIM
on or around 1 October 2021.
A further announcement will be made at the appropriate time.
Total voting rights
The Company's issued share capital as at the date of this
announcement comprises 350,334,730 ordinary shares of 25p each,
with one voting right per share ("Ordinary Shares"). The Company
does not hold any ordinary shares in treasury and therefore the
total number of Ordinary Shares with voting rights in the Company
is 350,334,730. This figure may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the share capital of the Company under the FCA's
Disclosure Guidance and Transparency Rules.
Defined terms used in this announcement shall have the same
meaning as in the announcement of 11 August 2021 unless otherwise
defined herein.
- ENDS -
Notes for editors
Advanced Oncotherapy plc www.avoplc.com
Dr. Michael Sinclair, Executive Chairman Tel: +44 (0) 20 3617 8728
Nicolas Serandour, CEO
Allenby Capital Limited (Nomad and Joint Broker)
Nick Athanas / Liz Kirchner (Corporate Finance) Tel: +44 (0) 20 3328 5656
Amrit Nahal / Matt Butlin (Sales and Corporate Broking)
SI Capital Ltd (Joint Broker)
Nick Emerson Tel: +44 (0) 1483 413 500
Jon Levinson Tel: +44 (0) 20 3871 4066
FTI Consulting (Financial PR & IR) advancedoncotherapy@fticonsulting.com
Simon Conway / Rob Winder Tel: +44 (0) 20 3727 1000
About Advanced Oncotherapy Plc
Advanced Oncotherapy, a UK headquartered company with offices in
London, Geneva, The Netherlands and in the USA, is a provider of
particle therapy with protons that harnesses the best in modern
technology. Advanced Oncotherapy's team "ADAM," based in Geneva,
focuses on the development of a proprietary proton accelerator
called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's
compact configuration delivers proton beams in a way that
facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with innovative
technology as well as expected lower treatment-related side
effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSSLESEEFSEEU
(END) Dow Jones Newswires
September 03, 2021 02:00 ET (06:00 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2023 to Apr 2024